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Background: The “stent sandwich” technique for the management of drug eluting stent (DES) in-stent restenosis has been associated with high 
rates of target lesion revascularization (TLR) ranging up to 28%. The optimal strategy for treating patients with DES restenosis, however still remains 
uncertain. In this study, we sought to compare the outcomes of patients with DES restenosis treated by reintervention with the same stent design 
versus crossing over to use an alternate DES design.
Methods: We retrospectively analyzed all patients who presented with a DES restenosis from June 2003 to March 2009. The primary end-point 
examined was need for repeat TLR at 2 years. A multivariate logistic regression model was completed for all variables utilizing a backwards selection 
technique. Events at 2 years were analyzed using Kaplan-Meier survival analysis.
Results: A total of 72 lesions (69 patients) were treated for DES restenosis. Sixty-one lesions had an index sirolimus (84.7%), 10 a paclitaxel 
(13.9%) and 1 an everolimus stent (1.4%). Thirty-one lesions (43.1%) were treated with the same stent and 41 lesions (56.9%) with alternate stent. 
Mean follow-up was 31 ± 16 months, with 1 patient having an in-hospital death. Baseline characteristics were comparable between groups, except 
that the alternate stent group had a higher incidence of hyperlipidemia (95.0% vs. 74.2% p=0.01) and non-focal (>10mm) lesions (42.5% vs.16.0%, 
p=0.02). There was no difference between stent diameter (2.9 ± 0.4 vs. 2.8 ± 0.4, p=0.8), stent length (25.0 ± 17.3 vs. 26.6 ± 16.9, p=0.7), and 
vessel treated (p=0.6). Overall MACE at 2 years was 27.9% and TLR was 20.6%. MACE at 2 years was higher in patients with same stent design 
(47.5% vs. 17.2%, p= 0.032). Repeat TLR at 2 years was significantly lower in lesions treated with an alternative stent (11.2%) versus lesions treated 
with the same stents (35.2%, p=0.043). Multivariate analysis revealed that alternative stenting (OR 0.17, 95% CI 0.05-0.63) and patient age (OR for 
each 1 year of age 1.07, 95% CI 1.01-1.13) were independent predictors of follow-up TLR.
Conclusion: In patients with DES restenosis, crossing over to an alternative DES design is associated with superior follow-up outcomes.
